Card image cap

GDPR: Considerations for Global Life Sciences Companies

Level: Advanced
Runtime: 92 minutes
Recorded Date: September 07, 2017
Click here to share this program
Printer-Friendly Version


  • GDPR Key Considerations
  • How Life Sciences Companies are Preparing
  • GDPR’s Unique Impact on Life Science Companies
  • Conclusion
  • Q & A
Runtime: 1 hour and 32 minutes
Recorded: September 7, 2017


Any data that American companies obtain on European citizens is subject to the EU's much more stringent privacy laws. Europeans have enhanced their privacy laws with the General Data Protection Regulation (GDPR), which addresses the export of personal data outside of the EU. The regulation was adopted on April 27, 2016 and it takes effect on in May of 2018.

Global health care companies need to revamp their privacy compliance programs in order to meet these new requirements. This is a big development for privacy officers and compliance departments of Life Sciences companies.

Most other countries followed the Europeans with the European Privacy Directive and will likely follow suit with this new privacy regulatory framework as well. As such, the implications for global health companies is very significant with respect to electronic health data.

Our team of experts will share their experiences in how they are developing plans to meet the objectives of these new rules.

This program was recorded on September 7th, 2017.

Provided By

American Bar Association
Card image cap


Card image cap

Karen Sewell

AbbVie, Inc.

Karen Sewell is an attorney practicing data privacy and security law, including global and cross-border counseling, privacy program design and maintenance and data breach response. She leads AbbVie Inc.'s global privacy team providing support to all of AbbVie's departments across all jurisdictions. Karen began her career in private practice at Baker & McKenzie and McGuireWoods practicing in global disputes, antitrust and general commercial litigation.

She holds a JD from the College of Law at the University of Illinois Urbana-Champaign and a BS in Journalism from Northwestern University.

Card image cap

Peter Blenkinsop

Drinker Biddle & Reath LLP

Peter A. Blenkinsop is a Partner at Drinker Biddle Reath LLP and advises clients on data privacy, research compliance, and e-health. He co-chairs the firm’s Information Privacy, Security & Governance practice. Peter represents clients in the life sciences, health, nutrition, and technology sectors, among others.

Peter’s focus on data privacy and security law began well over a decade ago in the run up to implementation of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). Since then, his practice has expanded well beyond health information privacy to data privacy and security generally. He advises companies on compliance issues raised by US federal and state privacy laws such as the Children’s Online Privacy Protection Act (“COPPA”), the CAN-SPAM Act, the Telephone Consumer Protection Act, and the Junk Fax Prevention Act. In this role, he assists clients in identifying privacy and security risks and developing information governance programs.

Peter also advises companies on compliance with international data transfer issues under the EU Data Protection Directive and other foreign privacy laws. He has assisted a number of multinationals in the development of their global privacy compliance programs. He regularly monitors and reports to clients on developments in data privacy laws worldwide.

As a member of the life sciences and pharmaceutical practices, Peter assists health industry clients with legal issues related to medical research, including clinical trials compliance, collection and use of human biological samples, and international research requirements. He advises companies on compliance with the Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) human subject protection regulations, as well as guidelines for medical research issued by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), World Health Organization, and World Medical Association.

Peter also advises companies on compliance with FDA and Federal Trade Commission (FTC) requirements related to the marketing of drugs, devices, and consumer healthcare products. This includes advising companies on development of mobile health applications, health websites, and health and fitness wearables.

Peter has a BA from Yale University and a JD from Georgetown University Law Center.

Card image cap

Similar Courses

Card image cap
64 minutes
"I Am Not a Cat" Proceedings in a Virtual World
Besides becoming a pop-culture catchphrase, how has the shift to a virtual environment impacted proceedings over the last year, and what changes do you believe are here to stay? Our panel of experts will examine some of the greatest challenges, faux pas, and successes in virtual proceedings over the course of this transformative time.

Women, Influence & Power in Law Conference


Add to Cart
Card image cap
63 minutes
2021: The Year of the ELM
Panelists will clarify what constitutes an ELM platform, examine its unique and compelling capabilities, and discuss its strategic and tactical advantages, particularly those stemming from data-driven insights and machine-driven decision making. Attendees will gain a clear understanding of the significance of the emergence of ELM solutions, what firms and law departments can achieve with ELM platform, and practical and ethical considerations related to adopting an ELM solution.



Add to Cart
Card image cap
97 minutes
26 Words that Created the Internet - Basics of the Communications Decency Act Section 230 Safe Harbor
This program will examine the basics of CDA 230 and its day to day affect for those who advise internet businesses as well as those who litigate against them. It will give practical guidance as to what extend internet companies can or should edit or censor the information their users contribute to their sites and to what extent those users will actually be liable.

New Media Rights


Add to Cart
Card image cap
63 minutes
40 Years of Data: What the Data on the Industry Says About Its Future
For 40 years, The American Lawyer, its affiliate publications and ALM Intelligence’s Legal Compass have been collecting data on law firms, clients and providers. What does the data tell us about where the industry is headed? We will take a deep dive into our data and others’ to assess the state of the industry and its future.



Add to Cart
Previous Next